Back

β-2-qlikoprotein 1 IgM

30 Azn
Add to basketAdded

Beta-2-glycoprotein 1 (β-2-GP1) antibodies are autoantibodies involved in blood clotting disorders. They belong to the antiphospholipid antibody group, which is commonly associated with vascular diseases and pregnancy complications.

Clinical Significance

  • β-2-GP1 IgM, IgG, and IgA antibodies are tested in connection with antiphospholipid syndrome (APS), cardiolipin antibodies, and lupus anticoagulant tests, as they target phospholipid layers in red blood cell membranes.
  • Although the exact mechanism is unclear, these antibodies contribute to the formation of arterial and venous thrombosis.
  • Most commonly found in autoimmune diseases, particularly APS, leading to:
    • Blood clotting abnormalities
    • Severe thrombocytopenia (low platelet count)
    • Preeclampsia (high blood pressure and protein in urine during pregnancy)
    • Recurrent pregnancy loss (especially in the 1st and 2nd trimesters)
  • IgM testing is particularly important in early APS detection, as IgM is the first antibody produced in an immune response.
  • Take the test at least 2 hours after the last meal.
  • Avoid smoking for 3 hours before the test.
  • Avoid physical and emotional stress for 1 hour before the test.
  • Suspected Antiphospholipid Syndrome (APS)
  • Unexplained venous thrombosis
  • Recurrent pregnancy loss

Positive β-2-GP1 IgM Test May Indicate:

  • Antiphospholipid Syndrome (APS)

Negative β-2-GP1 IgM Test:

  • No evidence of APS or related clotting disorders.

Clinical Importance

  • APS is a serious autoimmune disorder that can cause life-threatening blood clots, miscarriages, and pregnancy complications.
  • β-2-GP1 IgM antibodies are crucial for early detection of APS and monitoring clotting risks.
  • If APS is suspected but IgM and IgG results are negative, IgA testing should be performed.

This test plays a critical role in diagnosing APS and preventing severe thrombotic and pregnancy-related complications.